{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:49:16Z","timestamp":1793375356131,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-025-03968-7","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:49:09Z","timestamp":1771901349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy \u2013 an analysis of Swiss pharmacovigilance data"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-4803","authenticated-orcid":false,"given":"C\u00e9line K.","family":"St\u00e4uble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriu","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stammschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Allemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette E.","family":"Meyer zu Schwabedissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"3","key":"3968_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693\u2013705. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00430.x","journal-title":"Br J Pharmacol"},{"key":"3968_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107073","volume":"209","author":"W Kiander","year":"2025","unstructured":"Kiander W, Sinokki A, Neuvonen M, Kidron H, Niemi M (2025) Comparative uptake of statins by hepatic organic anion transporting polypeptides. Eur J Pharm Sci 209:107073. https:\/\/doi.org\/10.1016\/j.ejps.2025.107073","journal-title":"Eur J Pharm Sci"},{"key":"3968_CR3","unstructured":"Drug Interaction Studies M12. ICH Harmonised Guideline Accessed: Jan. 08, 2025. [Online]. Available: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf"},{"issue":"5","key":"3968_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","volume":"75","author":"DW Schneck","year":"2004","unstructured":"Schneck DW et al (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75(5):455\u2013463. https:\/\/doi.org\/10.1016\/j.clpt.2003.12.014","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3968_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","volume":"73","author":"C Kyrklund","year":"2003","unstructured":"Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73(6):538\u2013544. https:\/\/doi.org\/10.1016\/S0009-9236(03)00052-3","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3968_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1067\/mcp.2000.108507","volume":"68","author":"JT Backman","year":"2000","unstructured":"Backman JT, Kyrklund C, Kivist\u00f6 KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68(2):122\u2013129. https:\/\/doi.org\/10.1067\/mcp.2000.108507","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"3968_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/pds.977","volume":"13","author":"JT Chang","year":"2004","unstructured":"Chang JT, Staffa JA, Parks M, Green L (2004) Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13(7):417\u2013426. https:\/\/doi.org\/10.1002\/pds.977","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3968_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","volume":"95","author":"PH Jones","year":"2005","unstructured":"Jones PH, Davidson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate\u2009+\u2009statin versus gemfibrozil\u2009+\u2009any statin. Am J Cardiol 95(1):120\u2013122. https:\/\/doi.org\/10.1016\/j.amjcard.2004.08.076","journal-title":"Am J Cardiol"},{"issue":"7","key":"3968_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/00498250500136676","volume":"35","author":"M Yamazaki","year":"2005","unstructured":"Yamazaki M et al (2005) Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35(7):737\u2013753. https:\/\/doi.org\/10.1080\/00498250500136676","journal-title":"Xenobiotica"},{"key":"3968_CR10","unstructured":"Swissmedic Arzneimittelinformation Accessed: Jan. 14, 2025. [Online]. Available: https:\/\/www.swissmedicinfo.ch"},{"issue":"5","key":"3968_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM et al (2022) The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther 111(5):1007\u20131021. https:\/\/doi.org\/10.1002\/cpt.2557","journal-title":"Clin Pharmacol Ther"},{"key":"3968_CR12","unstructured":"Research (2025) For Healthcare Professionals | FDA\u2019s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems, FDA, June Accessed: 26 Aug 2025. [Online]. Available: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems"},{"issue":"3","key":"3968_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740338.2011.540568","volume":"10","author":"TT Abd","year":"2011","unstructured":"Abd TT, Jacobson TA (2011) Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10(3):373\u2013387. https:\/\/doi.org\/10.1517\/14740338.2011.540568","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"3968_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A et al (2014) Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 96(4):470\u2013476. https:\/\/doi.org\/10.1038\/clpt.2014.121","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3968_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","volume":"23","author":"C Buettner","year":"2008","unstructured":"Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ (2008) Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23(8):1182\u20131186. https:\/\/doi.org\/10.1007\/s11606-008-0636-7","journal-title":"J Gen Intern Med"},{"key":"3968_CR16","unstructured":"Schur N et al (2020) Helsana-Arzneimittelreport f\u00fcr die Schweiz 2020., Accessed 20 Oct 2022. [Online]. Available: https:\/\/www.helsana.ch\/de\/helsana-gruppe\/medien-publikationen\/mitteilungen\/arzneimittelreport-2020.html"},{"issue":"11","key":"3968_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban M-C et al (2017) Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol 69(11):11. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.036","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3968_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/archinternmed.2008.552","volume":"169","author":"V Shalev","year":"2009","unstructured":"Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD (2009) Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 169(3):260\u2013268. https:\/\/doi.org\/10.1001\/archinternmed.2008.552","journal-title":"Arch Intern Med"},{"key":"3968_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3247","author":"CK St\u00e4uble","year":"2024","unstructured":"St\u00e4uble CK, Lampert ML, Allemann SS, Meyer zu Schwabedissen HE (2024) A clinical practice perspective on the evaluation of OATP1B1-associated drug interactions. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3247","journal-title":"Clin Pharmacol Ther"},{"key":"3968_CR20","doi-asserted-by":"publisher","unstructured":"Gastaldi G et al (2023) Swiss recommendations of the Society for Endocrinology and Diabetes (SGED\/SSED) for the treatment of type 2 diabetes mellitus (2023), Swiss Med. Wkly., vol 153, no. 4, pp 40060\u201340060,\u00a0https:\/\/doi.org\/10.57187\/smw.2023.40060","DOI":"10.57187\/smw.2023.40060"},{"key":"3968_CR21","unstructured":"Schur N et al (2023) Helsana-Arzneimittelreport f\u00fcr die Schweiz 2023. Accessed 14 Dec 2023. [Online]. Available: https:\/\/reports.helsana.ch\/arzneimittel2023\/"},{"issue":"3","key":"3968_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cpt.406","volume":"100","author":"P Stopfer","year":"2016","unstructured":"Stopfer P et al (2016) Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther 100(3):259\u2013267. https:\/\/doi.org\/10.1002\/cpt.406","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3968_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13318-017-0427-9","volume":"43","author":"P Stopfer","year":"2018","unstructured":"Stopfer P et al (2018) Effects of metformin and furosemide on rosuvastatin pharmacokinetics in healthy volunteers: implications for their use as probe drugs in a transporter cocktail. Eur J Drug Metab Pharmacokinet 43(1):69\u201380. https:\/\/doi.org\/10.1007\/s13318-017-0427-9","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"3968_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"J Keskitalo","year":"2009","unstructured":"Keskitalo J, Zolk O, Fromm M, Kurkinen K, Neuvonen P, Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86(2):197\u2013203. https:\/\/doi.org\/10.1038\/clpt.2009.79","journal-title":"Clin Pharmacol Ther"},{"key":"3968_CR25","unstructured":"Fachinfo-Service Accessed 05 Jun 2025. [Online]. Available: https:\/\/www.fachinfo.de\/"},{"key":"3968_CR26","unstructured":"FDA Online Label Repository., Accessed 05 Jun 2025. [Online]. Available: https:\/\/open.fda.gov\/fdalabels\/"},{"issue":"3","key":"3968_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1124\/dmd.112.049023","volume":"41","author":"E van de Steeg","year":"2013","unstructured":"van de Steeg E et al (2013) Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab Dispos 41(3):592\u2013601. https:\/\/doi.org\/10.1124\/dmd.112.049023","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"3968_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/FPC.0b013e3283620c3b","volume":"23","author":"B Tamraz","year":"2013","unstructured":"Tamraz B et al (2013) OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics 23(7):355\u2013364. https:\/\/doi.org\/10.1097\/FPC.0b013e3283620c3b","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"3968_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2337\/db07-1515","volume":"57","author":"I Bachmakov","year":"2008","unstructured":"Bachmakov I, Glaeser H, Fromm MF, K\u00f6nig J (2008) Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57(6):1463\u20131469. https:\/\/doi.org\/10.2337\/db07-1515","journal-title":"Diabetes"},{"issue":"9","key":"3968_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40262-020-00976-x","volume":"60","author":"AB Jordy","year":"2021","unstructured":"Jordy AB et al (2021) Effect of oral semaglutide on the pharmacokinetics of levonorgestrel and ethinylestradiol in healthy postmenopausal women and furosemide and rosuvastatin in healthy subjects. Clin Pharmacokinet 60(9):1171\u20131185. https:\/\/doi.org\/10.1007\/s40262-020-00976-x","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3968_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FPC.0b013e3282fe9a2c","volume":"18","author":"S Oswald","year":"2008","unstructured":"Oswald S et al (2008) Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics 18(7):559. https:\/\/doi.org\/10.1097\/FPC.0b013e3282fe9a2c","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"3968_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2434","volume":"111","author":"E Kimoto","year":"2022","unstructured":"Kimoto E et al (2022) Biomarker-informed model-based risk assessment of organic anion transporting polypeptide 1B mediated drug-drug interactions. Clin Pharmacol Ther 111(2):404\u2013415. https:\/\/doi.org\/10.1002\/cpt.2434","journal-title":"Clin Pharmacol Ther"},{"key":"3968_CR33","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/DDDT.S146863","volume":"11","author":"CH Kim","year":"2017","unstructured":"Kim CH, An H, Kim SH, Shin D (2017) Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Des Devel Ther 11:3461\u20133469. https:\/\/doi.org\/10.2147\/DDDT.S146863","journal-title":"Drug Des Devel Ther"},{"key":"3968_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2147\/DDDT.S158408","volume":"12","author":"H Kim","year":"2018","unstructured":"Kim H et al (2018) Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug Des Devel Ther 12:815\u2013821. https:\/\/doi.org\/10.2147\/DDDT.S158408","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"3968_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70041","volume":"17","author":"J Kinzi","year":"2024","unstructured":"Kinzi J, Grube M, Seibert I, Siegmund W, Meyer zu Schwabedissen HE (2024) Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe. Clin Transl Sci 17(10):e70041. https:\/\/doi.org\/10.1111\/cts.70041","journal-title":"Clin Transl Sci"},{"issue":"6","key":"3968_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1124\/dmd.110.036129","volume":"39","author":"T Watanabe","year":"2011","unstructured":"Watanabe T et al (2011) Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39(6):1031\u20131038. https:\/\/doi.org\/10.1124\/dmd.110.036129","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"3968_CR37","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1124\/dmd.115.065938","volume":"43","author":"MK Itkonen","year":"2015","unstructured":"Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT (2015) Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. Drug Metab Dispos 43(11):1655\u20131660. https:\/\/doi.org\/10.1124\/dmd.115.065938","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"3968_CR38","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1124\/dmd.116.070276","volume":"44","author":"S-J Kim","year":"2016","unstructured":"Kim S-J et al (2016) Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab Dispos Biol Fate Chem 44(10):1622\u20131632. https:\/\/doi.org\/10.1124\/dmd.116.070276","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"3968_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1124\/dmd.115.066795","volume":"44","author":"R Elsby","year":"2016","unstructured":"Elsby R, Martin P, Surry D, Sharma P, Fenner K (2016) Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos 44(3):398\u2013408. https:\/\/doi.org\/10.1124\/dmd.115.066795","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"3968_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00228-018-2477-6","volume":"74","author":"Q Pei","year":"2018","unstructured":"Pei Q et al (2018) Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol 74(8):1021\u20131028. https:\/\/doi.org\/10.1007\/s00228-018-2477-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3968_CR41","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1016\/j.xphs.2019.08.012","volume":"108","author":"H Murata","year":"2019","unstructured":"Murata H, Ito S, Kusuhara H, Nomura Y, Taniguchi T (2019) Proposal of a parameter for OATP1B1 inhibition screening at the early drug discovery stage. J Pharm Sci 108(12):3898\u20133902. https:\/\/doi.org\/10.1016\/j.xphs.2019.08.012","journal-title":"J Pharm Sci"},{"issue":"1","key":"3968_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2236","volume":"110","author":"SW Yee","year":"2021","unstructured":"Yee SW et al (2021) Drugs in COVID-19 clinical trials: predicting transporter-mediated drug-drug interactions using in vitro assays and real-world data. Clin Pharmacol Ther 110(1):108\u2013122. https:\/\/doi.org\/10.1002\/cpt.2236","journal-title":"Clin Pharmacol Ther"},{"key":"3968_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1875397301004010001","volume":"4","author":"C Gui","year":"2010","unstructured":"Gui C, Obaidat A, Chaguturu R, Hagenbuch B (2010) Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1\u20138. https:\/\/doi.org\/10.2174\/1875397301004010001","journal-title":"Curr Chem Genomics"},{"issue":"1","key":"3968_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","volume":"64","author":"G Burgess","year":"2008","unstructured":"Burgess G, Hoogkamer H, Collings L, Dingemanse J (2008) Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 64(1):43\u201350. https:\/\/doi.org\/10.1007\/s00228-007-0408-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3968_CR45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/00498254.2019.1709133","volume":"50","author":"S Ogawa","year":"2020","unstructured":"Ogawa S, Shimizu M, Yamazaki H (2020) Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal\/hepatic impairment. Xenobiotica 50(9):1023\u20131031. https:\/\/doi.org\/10.1080\/00498254.2019.1709133","journal-title":"Xenobiotica"},{"issue":"2","key":"3968_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s13318-016-0349-y","volume":"42","author":"S Ayalasomayajula","year":"2017","unstructured":"Ayalasomayajula S et al (2017) Assessment of drug\u2013drug interaction potential between atorvastatin and LCZ696, a novel angiotensin receptor neprilysin inhibitor, in healthy Chinese male subjects. Eur J Drug Metab Pharmacokinet 42(2):309\u2013318. https:\/\/doi.org\/10.1007\/s13318-016-0349-y","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"3968_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.clpt.2004.07.008","volume":"76","author":"M Hermann","year":"2004","unstructured":"Hermann M, \u00c5sberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JLE (2004) Substantially elevated levels of Atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 76(4):388\u2013391. https:\/\/doi.org\/10.1016\/j.clpt.2004.07.008","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3968_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/107424840100600404","volume":"6","author":"J-W Park","year":"2001","unstructured":"Park J-W et al (2001) Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 6(4):351\u2013361. https:\/\/doi.org\/10.1177\/107424840100600404","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"3968_CR49","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5414\/cpp40439","volume":"40","author":"JW Park","year":"2002","unstructured":"Park JW et al (2002) Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 40(10):439\u2013450. https:\/\/doi.org\/10.5414\/cpp40439","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"3968_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.266","volume":"87","author":"S Oswald","year":"2010","unstructured":"Oswald S et al (2010) Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 87(6):6. https:\/\/doi.org\/10.1038\/clpt.2009.266","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3968_CR51","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jnnp.68.6.750","volume":"68","author":"RF Duyff","year":"2000","unstructured":"Duyff RF, den Bosch JV, Laman DM, van Loon B-JP, Linssen WHJP (2000) Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 68(6):750\u2013755. https:\/\/doi.org\/10.1136\/jnnp.68.6.750","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"3968_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2014the PRIMO study. Cardiovasc Drugs Ther 19(6):403\u2013414. https:\/\/doi.org\/10.1007\/s10557-005-5686-z","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"3968_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/cpt.525","volume":"101","author":"T Prueksaritanont","year":"2017","unstructured":"Prueksaritanont T et al (2017) Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther 101(4):519\u2013530. https:\/\/doi.org\/10.1002\/cpt.525","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3968_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","volume":"29","author":"M Karlgren","year":"2012","unstructured":"Karlgren M, Ahlin G, Bergstr\u00f6m CAS, Svensson R, Palm J, Artursson P (2012) In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug\u2013drug interactions. Pharm Res 29(2):411\u2013426. https:\/\/doi.org\/10.1007\/s11095-011-0564-9","journal-title":"Pharm Res"},{"issue":"2","key":"3968_CR55","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jiz439","volume":"221","author":"MP Kosloski","year":"2020","unstructured":"Kosloski MP et al (2020) Drug-drug interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. J Infect Dis 221(2):223\u2013231. https:\/\/doi.org\/10.1093\/infdis\/jiz439","journal-title":"J Infect Dis"},{"issue":"3","key":"3968_CR56","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cjca.2018.11.005","volume":"35","author":"DD Waters","year":"2019","unstructured":"Waters DD, Hsue PY (2019) Lipid abnormalities in persons living with HIV infection. Can J Cardiol 35(3):249\u2013259. https:\/\/doi.org\/10.1016\/j.cjca.2018.11.005","journal-title":"Can J Cardiol"},{"issue":"2","key":"3968_CR57","doi-asserted-by":"publisher","first-page":"e01060","DOI":"10.1002\/prp2.1060","volume":"11","author":"R Elsby","year":"2023","unstructured":"Elsby R, Coghlan H, Edgerton J, Hodgson D, Outteridge S, Atkinson H (2023) Mechanistic in vitro studies indicate that the clinical drug\u2013drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3. Pharmacol Res Perspect 11(2):e01060. https:\/\/doi.org\/10.1002\/prp2.1060","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"3968_CR58","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385\u2013396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"issue":"5","key":"3968_CR59","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","volume":"27","author":"GBJ Mancini","year":"2011","unstructured":"Mancini GBJ et al (2011) Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian working group consensus conference. Can J Cardiol 27(5):635\u2013662. https:\/\/doi.org\/10.1016\/j.cjca.2011.05.007","journal-title":"Can J Cardiol"},{"issue":"7","key":"3968_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","volume":"14","author":"M Niemi","year":"2004","unstructured":"Niemi M et al (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenet Genomics 14(7):429. https:\/\/doi.org\/10.1097\/01.fpc.0000114750.08559.32","journal-title":"Pharmacogenet Genomics"},{"issue":"17","key":"3968_CR61","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","volume":"54","author":"D Voora","year":"2009","unstructured":"Voora D et al (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54(17):1609\u20131616. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.053","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3968_CR62","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16(12):873. https:\/\/doi.org\/10.1097\/01.fpc.0000230416.82349.90","journal-title":"Pharmacogenet Genomics"},{"key":"3968_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41431-024-01769-7","volume":"33","author":"DFGJ Wolthuis","year":"2024","unstructured":"Wolthuis DFGJ et al (2024) Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. Eur J Hum Genet 33:1\u20138. https:\/\/doi.org\/10.1038\/s41431-024-01769-7","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"3968_CR64","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1177\/0091270011427907","volume":"52","author":"CL Aquilante","year":"2012","unstructured":"Aquilante CL et al (2012) Influence of SLCO1B1 polymorphisms on the drug-drug interaction between Darunavir\/Ritonavir and Pravastatin. J Clin Pharmacol 52(11):1725\u20131738. https:\/\/doi.org\/10.1177\/0091270011427907","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3968_CR65","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/clpt.2008.74","volume":"84","author":"A Kalliokoski","year":"2008","unstructured":"Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M (2008) Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 84(4):488\u2013496. https:\/\/doi.org\/10.1038\/clpt.2008.74","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"3968_CR66","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","volume":"53","author":"S Suwannakul","year":"2008","unstructured":"Suwannakul S et al (2008) Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet 53(10):899\u2013904. https:\/\/doi.org\/10.1007\/s10038-008-0324-9","journal-title":"J Hum Genet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03968-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:52:57Z","timestamp":1773309177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3968"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03968-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not fulfill the criteria for research according to the Swiss Human Research Act and therefore was exempt from ethics approval from a competent cantonal ethics committee. This research study was conducted retrospectively from anonymously collected data of individual case safety reports obtained from the Swissmedic database. It was ensured that all data collected was fully anonymized and handled in compliance with Swiss data protection regulations, thereby adhering to ethical research standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was not required as all information analysed and reported is fully anonymized and not traceable to an individual.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}